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Abstract: Psoriatic arthritis (PsA) is an underdiagnosed entity with a broad impact on the quality of life. Although the pathogenesis
is largely unknown, autoimmune footprints of the inflammation in PsA have increasingly been recognized. Most of the genetic
variation predisposing to PsA is mapped to the class I major histocompatibility complex (MHC) region and shared by a variety of
autoimmune diseases. Polymorphisms in the genes IL12B, IL23R, IL13, TNIP1, TRAF3IP2, TYK2, and many others explain the nonHLA genetic risk with little known functional consequences. Entheseal and synovial cellular infiltrate with oligoclonal CD8+ T cells and
occasional germinal centers, loss of regulatory T cell function, and specific autoantibodies such as anti-PsA peptide, anti-LL-37, and
anti-ADAMTSL5 are the immunopathological findings suggestive of autoimmunity. These were supported by clinical observations of
autoimmune multimorbidity and treatment response to calcineurin/mTOR and co-stimulation inhibition.
Key words: Autoantibody, autoimmunity, genetic, psoriasis, psoriatic arthritis

1. Introduction
Psoriatic arthritis (PsA) is a chronic inflammatory
disease that usually affects the joints, tendons, ligaments
and their attachment sites, the entheses. According
to a systematic review of the epidemiological studies,
the prevalence of PsA ranged between 6% to 24% in
patients with psoriasis when validated criteria such as
Moll and Wright, classification of psoriatic arthritis
(CASPAR), or European spondylarthropathy study group
criteria (ESSG) were applied [1]. When the Psoriasis
and Arthritis Questionnairre (PAQ) was applied, up to
half of the patients defined active or past inflammatory
manifestations [2]. Despite the high prevalence, PsA is still
an underdiagnosed clinical entity in daily clinical practice
such that undiagnosed cases constitute the majority [3].
The impact of PsA appears to be very broad and covers all
aspects of life [4–6].
Psoriasis is occasionally accompanied by inflammatory
conditions other than arthritis such as uveitis and
inflammatory bowel disease. The concept of “psoriatic
disease” was introduced to encompass the inflammatory
involvement of several different organs/systems in the
same patient [7]. A common genetic background with
environmental triggers was proposed to underlie the
inflammatory changes in different organs. Although
the inflammatory manifestations such as arthritis and

bowel disease share common histopathological features
and cytokine profiles with the skin disease, the genetic
susceptibility to psoriasis and PsA do not totally overlap
(Figure) [8–17]. Since almost all patients with PsA in whom
genetic susceptibility was investigated had concurrent
psoriasis, most genes identified were relevant to psoriasis
susceptiblity as well [9]. However, certain genes seem to be
more frequently associated with PsA than psoriasis alone
(i.e. the PsA-weighted genes such as HLA-B, FBXL19, and
NOS2) (Figure) [8–11,13–17]. With these observations, the
management of psoriasis as a systemic disease has gained
attention over time [7,18]. Moreover, cardiovascular,
metabolic, and psychological disorders in patients with
psoriasis/PsA has been proposed to be included under a
broader umbrella term “systemic psoriatic disease” [19].
Although not directly caused by an apparent or intense
inflammation, diabetes, obesity, metabolic syndrome, fatty
liver disease, and atherosclerosis were speculated to be at
least contributed by the systemic inflammation in psoriasis/
PsA [18,19]. The potential reversal of these conditions with
the advancement of systemic antiinflammatory treatment
modalities is an area of active research.
PsA, like psoriasis, is considered as an immune-mediated
inflammatory disease with autoimmune and (auto)
inflammatory features [19,20]. Spondyloarthropathies
including PsA do not generally display the prototypical
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Figure. Genes implicated in susceptibility to psoriasis and psoriatic arthritis.

genetic, clinical, and immunological T- and/or B-cell
mediated autoimmune diseases and T- and B-cell
targeted therapies are usually not effective. Recurrent
attacks, interattack remissions, local triggers, and
prominently neutrophilic inflammation have made most
clinicians consider spondyloarthropathies as diseases of
autoinflammatory rather than autoimmune origin [21].
However, PsA is, perhaps, the “most autoimmune” disease
among spondyloarthritides. Autoimmune footprints of
the inflammation and autoimmune multimorbidity in
PsA, which are the main topics that will be covered in this
review, have increasingly been recognized.
2. Pathophysiological aspects
2.1. Genetic and epigenetic findings of autoimmunity in
PsA
Familial clustering of PsA has long been known [9,22,23].
The heritability of PsA is even greater than psoriasis [23].
Most of the germline genetic risk identified so far in
PsA is related to genes involved in the regulation of the
adaptive immune responses such as antigen presentation
and lymphocyte survival, function, differentiation, and
maturation [9]. Dysregulation of the adaptive immune
responses solely, of course, does not make a disease
“autoimmune” but it may be speculated to at least
contribute to the systemic inflammation and predispose
to autoimmunity particularly if it is considered that
similar genetic changes were shared by many autoimmune
diseases (see below). Polymorphisms in the genes involved
in the regulation of the innate immune responses such
as type I interferon (IFN) signaling, nuclear factor kappa
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B (NF-κB) activation, and nitric oxide production also
contribute to the genetic risk of PsA [8,9]. Innate immune
dysregulation has been known to modify the course of
autoimmune diseases [24]. Indeed, monogenic forms of
systemic lupus erythematosus (SLE), a prototype systemic
autoimmune disease, are mostly caused by mutations in
the genes involved in the regulation of the innate immune
responses such as nucleic acid sensing and degradation and
type I IFN signaling [25]. Major gene variants implicated
in PsA will be discussed below along with functional
consequences and possible autoimmunity-related features.
It should be noted that all genome-wide association
studies (GWAS) in PsA were performed only in European
ancestry cohorts [9,13,14]. Ethnic charactersitics of the
cohorts were of importance in previous linkage studies
in PsA [26] and GWAS in psoriasis [27]. Another
important point is that there is a paucity of studies that
report the functional consequences of the genetic changes
in PsA which makes the interpretation of the proposed
associations difficult. Although GWAS have identified a
significant proportion of the genetic risk to PsA over the
last decade, the biological translation of these findings
is not straightforward. GWAS typically assign singlenucleotide polymorphisms to the nearest gene but most
of the time many variants simultaneously exist with high
linkage disequilibrium. Despite advanced bioanalytical
methods such as functional enrichment, network-assisted
and pathway analyses, less than a half of the genetic
variation could be identified to be truely functionally
relevant in immune cells making functional studies
imperative to understand the disease pathogenesis and
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guide treatment strategies [28]. Functional studies even
may fail to determine the consequence(s) of a variation if
issues such as “cells or tissues of interest”, “stimulated or
resting state”, and “healthy or diseased subjects” are not
properly addressed [28].
2.1.1. Human leukocyte antigen (HLA) associations
After the identification of PSORiasis susceptibility
(PSORS1) gene on 6p21.3 as the major genetic determinant
of psoriasis, candidate gene and linkage studies confirmed
this association in PsA as well [9–11,29]. The PSORS1 risk
variant, carried by more than half and about one third of
the patients with psoriasis and PsA, respectively, was later
identified to be the HLA-C*06:02 (corresponding to the
HLA-Cw6 serotype) [30] and other polymorphisms in the
major histocompatibility complex (MHC) class I region
such as HLA-B*27, -B*38, and -B*39 have repeatedly
been noted in PsA but not in psoriasis [9–11,13–17,29].
According to the most recent genome-wide meta-analysis,
[13] association of most of the other loci in the MHC
region (including the non-HLA genes) with PsA seemed
to be attributable to linkage disequilibrium with the HLAB/‑C region as previously shown to be the case in psoriasis
as well [31]. HLA polymorphisms are not only related to
PsA risk but also the disease phenotype. HLA-B27 was
found to be associated with axial disease whereas HLA-B38
and -B39 were more frequent in peripheral polyarthritis
[9,10,29,32,33]. HLA-B39 was related to progressive
disease as well [32,33]. Some HLA polymorphisms that
were not associated with PsA risk independently may still
modify the disease course. HLA-DR7 (HLA-DRB1*07
gene product), an MHC class II antigen, was found
protective against disease progression and HLA-DQw3
(HLA-DQB1*03 gene product) was associated with
progressive disease but only in the absence of HLA-DR7
[33,34]. Importantly, PsA patients carrying rheumatoid
arthritis (RA) shared epitope alleles were found to have
more radiological erosions although their presence was
not linked to an increased PsA risk [35].
Given their strong risk association, explaining the
functional role of the HLA risk alleles, particularly the
HLA-C*06:02, is essential for elucidating the pathogenesis
of PsA. A fascinating case study with a unique methodology
identified ADAMTS-like 5 (ADAMTSL5) as an HLAC*06:02-presented melanocytic autoantigen to the lesioninfiltrating autoreactive CD8+ T cells in psoriasis [36].
More interestingly, peptide motifs of the HLA-C*07:01,
-C*07:02, and -B*27, which are three of the other psoriasis
risk-related leukocyte antigens, utilize the same anchor
residues with the HLA-C*06:02, have overlapping peptidebinding properties, and belong to the same HLA supertype
[37]. Synovial/entheseal counterpart of this picture is yet
to be studied but seems to be more complicated since
different disease phenotypes in PsA exhibit different

HLA associations and contribution of the HLA-C*06:02
polymorphism to PsA risk is lesser compared to psoriasis
[38].
Class I MHC molecules are predominantly found
anchored in the cell membrane as trimeric structures
consisting of a heavy chain, a bound peptide, and β2microglobulin. However, the heavy chains of the class I
MHC molecules can dissociate from the bound peptide
and β2-microglobulin and assume an open conformation
[39]. These free heavy chains can form homodi/trimers and
observed more frequently on the activated CD8+ T cells,
and are implicated in many metabolic and immune cellular
processes such as glucose uptake, cell growth, interleukin-2
(IL-2)-, and T cell receptor (TCR)-mediated signaling via
cis-interactions with the insulin, epidermal growth factor,
IL-2 receptors, and TCR, respectively [39,40]. HLA-C has
a weaker association with β2-microglobulin than HLA-A
or -B, making dissociation from β2-microglobulin and
bound peptide more favorable [40]. Interestingly, similar
is true for the HLA-B27 as well [41]. β2-microglobulin
liberated from the disintegrated MHC is also a trigger for
synoviocytes to release inflammatory mediators resulting
in tissue destruction [40].
An important feature of the HLA-C is its interaction
with killer immunoglobulin-like receptors (KIRs) mainly
expressed on the natural killer (NK) cells. One hundred
percent of the HLA-C types but only a minority of
the HLA-A and -B (but including HLA-B27) subsets
recognize KIRs [40]. Another consequence of the open
conformation and homodi/trimerization is activation of
the NK cells via altered binding to KIRs [39–41]. Inhibition
of binding of HLA-B27 homodimers to KIR-3DL2 by a
specific antibody to HLA-B27 homodimers resulted in
inhibition of survival and proliferation of KIR-3DL2+ NK
cells [42]. This antibody also inhibited production of IL17 by peripheral blood mononuclear cells from patients
with spondyloarthritis possibly via inhibition of binding
of HLA-B27 homodimers to KIR-3DL2 expressing CD4+ T
cells [42]. Recently, some KIR polymorphisms were shown
to be associated with PsA risk [43] although they were
not reported to be significant at the genome-wide level in
GWAS meta-analyses [13,14].
HLA-B and -C associations of significantly increased
genetic risk to selected autoimmune and immune
mediated inflammatory diseases are summarized in Table
1 [44–64]. Many autoimmune diseases such as type I
diabetes, myasthenia gravis, SLE, Sjögren’s syndrome,
pemphigus
vulgaris,
dermato/polymyositis,
and
vitiligo share HLA associations with PsA, the last being
associated with both HLA-C*06:02 and -B*27 [59,60]. It
is an interesting finding since CD8+ T cell autoreactivity
against a melanocyte antigen presented on HLA-C*06:02
was demonstrated in psoriasis [36] and peptide-binding
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Table 1. HLA-B and -C associations of the significantly increased genetic risk to selected autoimmune and immune mediated
inflammatory diseases.
Disease

Type I Diabetes

Dominant
MHC Association
Class II (HLA-DQ&-DR)

HLA-B and -C
Association

Effect size
(OR with 95% CI)

Ref.

B*18:01

2.05 (1.59-2.61)

44

B*39:06

10.31 (4.21-25.1)

44

C*03:03

1.48 (1.10-1.99)a

44

a
a

Autoimmune Thyroid Disease
Graves’ Disease

Class II (HLA-DQ&-DR)

B*08†

2.8 (1.81-4.33)b,c

45,46

Autoimmune Hypothyroidism

Class II (HLA-DQ&-DR)

-

-

46

B*08:01†

5.1 (2.48-10.5)d

Myasthenia Gravis

Class I&II (HLA-B,-C,&-DQ)

Multiple Sclerosis

Class II (HLA-DR)

Celiac Disease
Rheumatoid Arthritis
Systemic Lupus Erythematosus

C*07:01

1.85 (1.14-3.01)

47

C*15

2.58 (1.57-4.25)a

48

Class II (HLA-DQ)

-

-

49

Class II (HLA-DR)

-

-

Class II (HLA-DR)

Class II (HLA-DR&-DQ)

1.84 (1.7-1.99)

51

C*07:01†

1.57 (1.47-1.69)a

51

B*08

5.27 (2.31-12)

52

B*35:01

3.7 (1.92-7.12)c

Class II (HLA-DR)

C*07

5.23 (2.24-12.21)

54

-

-

55

B*38

4.32 (2.22-8.38)c

56

B*57

3.55 (1.64-7.65)

57

C*12

3.15 (1.87-5.3)c

56

C*15

2.97 (1.45-6.1)

57

B*37:01

8 (3.35-19.17)f

C*17

8.31 (2.46-28.16)

58

B*13

1.87 (1.23-2.84)f

59,60

B*27

2.29 (1.3-4.06)

59

C*06:02

3.04 (1.79-5.18)f

59,60

a

a

†

Systemic Sclerosis

50

B*08:01

†

†

Sjögren’s Syndrome

47
d

†

53
c

Autoimmune Bullous Diseases
Pemphigus Vulgaris

Bullous Pemphigoid

Vitiligo

Class II
(HLA-DR)
Class II
(HLA-DR&-DQ)
Class I&II
(HLA-A,-B,-C&-DR)

e

e

58
f

f

Autoimmune Liver Diseases
61

Autoimmune Hepatitis

Class II (HLA-DR)

-

-

Primary Biliary Cholangitis

Class II (HLA-DR)

-

-

Primary Sclerosing Cholangitis

Class II (HLA-DR)

B*08†

2.99 (1.83-4.9)c

63

B*08:01†

2.5 to 4.6

64

C*07:01

c

2.1 to 3.6

64

C*14

29.3 (2.68-1449.2)c

64

62

Idiopathic Inflammatory Myopathies
Polymyositis & Dermatomyositis
Inclusion Body Myositis

Class I&II (HLA-A,-B,-C,-DR&-DQ)
Class I&II (HLA-A,-B,-C,-DR&-DQ)

†

Abbreviations: HLA = Human leukocyte antigen, MHC = Major histocompatibility complex, OR = Odds ratio, CI = Confidence interval.
a
after accounting for linkage disequilibrium (LD) with dominant associations bprobably due to LD with HLA-DR c not tested for LD
d
controlled for each other. econtrolled for other HLA-B and -C alleles f controlled for other class I alleles tested.
†
the ancestral Caucasian haplotype AH8.1 (HLA-A*01:01 -C*07:01 -B*08:01 -DRB1*03:01 -DRB3*01:01 -DQA1*05:01 -DQB1*02:01)
relation may be of concern.
HLA-B and -C associations which overlap with increased psoriatic arthritis genetic risk are indicated in bold.
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properties of HLA-C*06:02 and -B*27 overlap [37]. Most
other associations of common genetic risk to PsA and
autoimmune diseases lie in the HLA-C*07:01, which is the
HLA-C constituent of the the ancestral Caucasian haplotype
AH8.1 (the Super B8, HLA-A*01:01-C*07:01-B*08:01DRB1*03:01-DRB3*01:01-DQA1*05:01-DQB1*02:01)
[65]. This particular haplotype and its fragments, carried
as a whole in 18% and at least as one constituent in
36%–39% of the healthy Caucasian population [66] and
more frequently in northern Europe, have been found to
be associated with numerous autoimmune diseases and
abnormal immune responses even in healthy population
(the 8.1 effect) [65]. It is important to underline here
again that the HLA-C*07:01, -C*06:02, and -B*27 belong
to the same HLA supertype according to peptide binding
properties [37].
2.1.2. Non-HLA associations in the MHC region
Although MHC class I polypeptide-related sequence A
(MICA), independent of the HLA-C*06:02, and tumor
necrosis factor-α (TNFA) genes were previously identified
as PsA risk regions in relatively small-scale studies, [67–
70] these findings could not be replicated in different
races and in large GWAS and meta-analyses [13,14], and
at least partially explainable by linkage disequilibrium
with the HLA-B and –C [9,10,33]. Anyway, MICA-A9
(MICA*002 gene product), expressed on various cell types
including keratinocytes, fibroblasts, and synoviocytes, was
speculated to act as a superantigen independent of antigen
presentation on the MHC [67]. More recently, different
MICA and MICB polymorphisms were implicated in
immune response since the products of these genes are
ligands for NKG2D (natural killer receptor group-2 D,
encoded by the gene killer cell lectin like receptor K1,
KLRK1), a master regulator of immune cell responsiveness
primarily expressed on all NK, NKT, and some T cell
subsets [71,72]. MICA/MICB-NKG2D interactions
result in phosphatidylinositol-3 kinase activation ending
up with many cellular processes like survival, activation,
and proliferation [71,72]. While one can doubt why
these innate immune response elements be important
to understand the autoreactivity in PsA, the fact is that
MICA and B polymorphisms are related to the genetic
risk in other autoimmune diseases such as celiac disease,
RA, and multiple sclerosis (MS) [73]. Experiments in
RA patients and in autoimmune encephalomyelitis and
collagen-induced arthritis models revealed the functional
consequences of MICA/MICB-NKG2D interactions such
as T cell autoreactivity, co-stimulation of TCR-mediated
cytokine release, and proliferation [73]. So, as previously
mentioned, innate immune dysregulation seems like more
than a bystander in autoimmune disease pathogenesis.
Many polymorphisms in the TNFA, particularly in
the promoter region, were reported to be related to PsA

risk either dependent or independent of the HLA-C*06:02
[69,70] but with inconsistent functional results, i.e. the
TNF-α mRNA and protein expression, in healthy people
and disease groups including PsA [74–76] Nevertheless,
the promoter polymorphisms of the TNFA are associated
with autoimmune diseases including SLE and RA [76].
Indeed, overexpression of only TNF-α was sufficient
enough to cause chronic severe erosive polyarthritis
resembling RA in mice transfected with human TNF-α
gene engineered for enhanced transcription [77].
2.1.3. Genetic associations outside the MHC region
Among more than 20 genetic susceptibility loci to PsA,
only few have consistent and strong associations [9,13,14]
(Figure) and will be reviewed here. But it is important to
underline that some polymorphisms not found to have
genome-wide significant effect on PsA risk in GWAS and
meta-analyses may still be players in disease pathogenesis.
One example is the KIR, polymorphisms of which were
found to be associated with PsA in case-control studies
[43] but not identified as a genetic risk region in large-scale
GWAS [13,14] although a functional consequence is likely
since class I MHC molecules (including HLA-C*06:02
and -B*27) are ligands for these receptors [39–42] but not
demonstrated in PsA or psoriasis to date. Interestingly,
functionally relevant combinations of HLA and KIR
genotypes may confer protection or susceptibility to PsA
[78]. KIR genes were also implicated in susceptibility to
RA [79].
2.1.3.1. Cytokine and cytokine receptor genes: IL-12
subunit β (p40) (IL12B), IL-23 receptor (IL23R), and
IL13
IL-12 subunit β (p40) is a component of both IL-12 and
-23. Biological activity and receptor binding of both
cytokines are conferred by the shared p40 subunit [80].
Although variation within IL12B and IL23R was shown
to be associated with PsA independent of both each
other and the MHC region [9,13,14], the functional
consequences of the implicated polymorphisms have not
been demonstrated clearly. Given the strong evidence of
IL-12 and IL-23/IL-17 axis driven inflammation in PsA,
the implicated polymorphisms were hypothesized to
alter the expression and/or function of these molecules.
This was further supported by the association of PsA risk
with rs321227 and rs2201841, which are located within
the 3’-untranslated (possibly affecting transcription)
and intergenic (possibly affecting splicing) regions of
the IL12B and IL23R, respectively [81,82]. rs11209026,
located in the Janus kinase 2 (JAK-2)-binding domain of
the IL23R, was found to be associated with PsA risk in at
least three different studies [9,81,82] and healthy people
carrying the low-risk minor variant (R381Q) were found
to have lower numbers of circulating Th17 and Tc17
cells compared to those carrying the wild-type variant
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[83]. More importantly, CD4+ and CD8+ T cells from
these individuals show decreased IL-23-mediated Th/c17
cytokine production and expansion [83]. Moreover, p40
subunit deficient mice were protected from developing
collagen-induced autoimmune arthritis, experimental
autoimmune antiglomerular basement membrane disease,
and experimental autoimmune encephalomyelitis [80]
highlighting the role of IL-23 in autoimmunity. Recently,
certain IL12B and IL23R polymorphisms were found to be
associated with alopecia areata in man [84] but they were
previously reported not to be associated with RA and SLE
[85,86].
IL13 polymorphisms were proposed as PsA markers
among psoriasis patients in the earlier reports [87,88] but
this gene was later identified as a risk region for cutaneousonly psoriasis as well albeit with a weaker association in a
large GWAS meta-analysis [13]. IL-13 is a Th2 cytokine
produced during allergic inflammation. It mediates the
survival of eosinophils, activation of fibroblasts (leading
to fibrosis), and immunoglobulin M (IgM)-to-IgE classswitch, and genetic polymorphisms in the IL13 were
mostly associated with asthma, allergic rhinitis, and atopic
dermatitis1 [87,88]. Although PsA patients were known to
have higher IL-13 levels in their synovial fluids (but not
sera) compared to patients with RA and osteoarthritis,
[89] the role of IL13 polymorphisms on that finding and in
the pathogenesis of PsA and autoimmune diseases remains
to be elucidated since IL-13 is generally considered as
an inhibitory regulator of Th1- and Th17-mediated
inflammation [90]. IL13 polymorphisms were not found
to be associated with genetic risk to type I diabetes,
RA, systemic sclerosis (SSc), and Sjögren’s syndrome
although serum IL-13 levels were mostly elevated [91].
Exceptionally, minor variant of the rs20541, previously
implicated in PsA, [87,88] was shown to be associated
with SLE and renal involvement in a case-control study
from China with significantly increased IL-13 levels in the
carriers [91]. But the result could not be replicated in an
SLE GWAS meta-analysis [92].
2.1.3.2. TNF-α-ınduced protein 3-interacting protein 1
(TNIP1) and TNF receptor associated factor 3-interacting
protein 2 (TRAF3IP2) genes
TNIP1 encodes a TNF-α-induced protein 3 (TNFAIP3 or
A20)-binding protein which plays a role in autoimmunity
and tissue homeostasis through the regulation (repression)
of NF-κB activation downstream of TNF-α and Toll-like
receptors. Polymorphisms in this gene have been associated
with psoriasis, PsA, RA, SLE, and SSc [93,94]. TNIP1 has
also been shown to function in signal repression even in

the absence of TNFAIP3 [94,95]. Like TNIP1, TNFAIP3
was identified as a genetic risk region for psoriasis and
PsA [9]. Notably, pathogenic mutations in TNFAIP3 cause
an autoinflammatory disease with autoimmune features,
haploinsufficiency of A20, in humans [95]. Experimental
overexpression of TNIP1 decreased cells’ responsiveness
to irritants and prevented an active state in vitro and a
lupus-like autoimmune phenotype was observed in mutant
TNIP1 knock-in mice but interestingly not in TNIP1
knock-out ones [94]. SLE, SSc, RA, and proriasis patients
carrying the variants of this gene were shown to have
altered mRNA and protein expression [93,94]. Possible
functional impacts of disease-related polymorphisms and
their exact role in the pathogenesis were not reported to be
studied in PsA.
TRAF3IP2 (Act1) was first identified as an ınhibitor
of NF-κB kinase (IKK)-binding protein and experimental
disruption of the IKK-binding domain of this protein
abolished NF-κB activation. Interestingly, it associates
with IL-17 receptor as well and expression of IL-17dependent inflammation-related genes was abolished in
Act1-deficient mouse cells. Binding of IL-17A/F to IL-17
receptor leads to recruitment of Act1 and this allows TNFreceptor associated factor 6 (TRAF6) binding to Act1. Act1TRAF6 signaling complex, then, mediates the downstream
activation of both NF-κB and mitogen activated protein
kinase (MAPK) pathways [96]. Act1 is also a negative
regulator of CD40- and B cell activating factor belonging
to the TNF family (BAFF)-mediated B cell survival [97].
Mice lacking TRAF3IP2 develop Sjögren’s syndrome
in association with lupus nephritis due to hyper-B cell
function but contrarily they show delayed and less severe
experimental autoimmune encephalomyelitis which
was thought to be IL-17 mediated [97]. TRAF6-binding
site of Act1 was needed to respond to IL-17 (but not to
TNF-α) and a polymorphism, rs33980500(C→T), nearby
this site was shown to be associated with psoriasis and
PsA2 [9,98]. Functional assays showed reduced binding of
this TRAF3IP2 variant to TRAF6 in PsA [98]. Missense
mutations in TRAF3IP2 in humans are associated with
chronic familial mucocutaneous candidiasis but not with
autoimmune disease1.
2.1.3.3. Nonreceptor tyrosine kinase 2 gene (TYK2)
TYK-2 plays an indispensable role in controlling responses
to multiple cytokines in humans. Interferon receptor
(IFNAR1) expression on the cell surface and signaling
through IL-6, -10, -12, and -23 receptors are dependent
on an intact TYK-2, which is involved in the activation (by
tyrosine phosphorylation) of multiple Janus kinase/signal

ClinVar (2021). Genomic variation and its relationship to human health [online]. Website https://www.ncbi.nlm.nih.gov/clinvar [accessed 19 March
2021].
1

Online Mendelian Inheritance in Man® (OMIM®) (2021). An Online Catalog of Human Genes and Genetic Disorders [online]. Website https://www.
omim.org [accessed 19 March 2021].)
2
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transducer and activator of transcription (JAK/STAT)
pathways in human T cells3. Pathogenic mutations of the
TYK-2 results in an immunodeficiency syndrome, the
Immunodeficiency-35, in man3. Polymorphisms of this
gene were found to be associated with a variety of immune
mediated inflammatory and autoimmune diseases
including psoriasis and PsA, MS, SLE, RA, type I diabetes,
idiopathic inflammatory myopathy, SSc, primary biliary
cholangitis, inflammatory bowel disease, and ankylosing
spondylitis [99]. While most minor alleles are protective,
the same polymorphic variant may be protective for
one disease but risky for another one [99]. Functional
consequences of many of these variants were studied in vitro
in human cell lines and in healthy and diseased subjects.
Splicing, mRNA and protein expression, enzymatic
activity, and downstream signaling were demonstrated to
be altered for some variants in different human diseases
[99]. Peripheral blood mononuclear cells and skin-homing
CD4+ and CD8+ lymphocytes from psoriasis patients
carrying the protective variant (rs12720356 encoding
I684S) manifested reduced phospho-STAT4 levels upon
stimulation compared to those carrying the wild-type and
risk-associated variant (rs34536443 encoding P1104A)
[100]. No study reported the functional consequences of
TYK2 variants in PsA.
2.1.4. Epigenetics and autoimmunity in PsA
Early studies identified a parent-of-origin effect
on the heritability of psoriasis and PsA (i.e. a more
prominent paternal transmission) [101]. This finding
was later linked to genomic imprinting, an epigenetic
phenomenon. Subsequent studies identified that
some genetic associations of PsA such as nucleotidebinding oligomerization domain-containing protein 2
(NOD2) and HLA-B*08 were more specific to paternally
transmitted disease [101]. Candidate gene and genomewide methylation, histone modification, regulatory RNA,
and chromatin remodelling studies followed these but
unfortunately only in psoriasis. Studies on the epigenetic
mechanisms of disease are scarce in PsA. A search with
the keyword “psoriatic arthritis” yielded only a total of six
results in the five PubMed/MEDLINE-indexed epigenetics
journals (Clinical Epigenetics, Environmental Epigenetics,
Epigenetics, Epigenomics, and Epigenetics & Chromatin
in alphabetical order) as of November 2020 none being a
PsA study. Similarly, search terms “psoriatic arthritis” and
“epigenetics” yielded 26 results in the entire PubMed, 19 of
which being reviews regarding psoriatic disease, with only
two epigenetic studies in PsA.
Global hypomethylation is a common feature of many
autoimmune and immune mediated inflammatory diseases
including PsA [101] and is proposed to lead to enhanced
gene expression and hyperactivity in T and B cells [102].
However, differential hypo/hypermethylation and histone
modifications such as acetylation, phosphorylation,

and ubiquitination of the particular genes (leading to
altered transcription) involved in immune functions and
microRNA-mediated post-transcriptional regulation of
expression are of concern. According to a pilot epigenomewide sperm/blood methylation study in psoriasis and PsA,
differentially methylated regions were found to be enriched
within the MHC but not in close proximity to the class I
gene loci [103]. Whether these represent distal regulatory
elements remains to be determined but top differentially
methylated regions contained potential biologically
relevant genes including HLA complex group 26 (HCG26,
which lies adjacent to the HLA complex P5 and between
the MICA and MICB, all of which are associated with
genetic risk to PsA and autoimmune diseases including
SLE, RA, and type I diabetes) and Integrin Subunit β2
(ITGB2) in PsA probands [103]. Although the effect of
hypo/hypermethylation of a gene region is predictable in
terms of expression, it still needs confirmatory functional
studies since an epivariation is only a small point in a
huge complex genetic background of PsA. Nevertheless,
variations in the HCG26 and ITGB2 were previously
reported to be associated with MS, type I diabetes, and RA
[104]1.
Peripheral blood microRNA profiles of patients
with active PsA were found to be different compared to
patients with inactive disease and healthy controls [105].
Pathway and interaction network analyses revealed some
differentially expressed microRNAs to be involved in TNF,
MAPK, and WNT signaling exclusively in active PsA. miR126-3p, highly downregulated in active PsA, was shown
to target and inhibit the expression of genes involved in
immune functions including phosphoinositide-3-kinase
regulatory subunit 2 (PI3KR2) and receptor activator
of NF-κB şigand (RANKL) in transfected human T cell
leukemia cell line [105]. Both miR-126-3p [106] and several
other dysregulated microRNAs in PsA were reported to be
of pathogenetic and even potential diagnostic importance
in autoimmune diseases including RA, SLE, MS, and
dermatomyositis [106,107].
2.2. Immunopathological findings of autoimmunity in
PsA
Genetic predisposition and triggers such as dysbiosis,
mechanical stress and injury, obesity, and infections
were proposed to cause aberrant immune cell activation
and secretion of inflammatory cytokines leading to
inflammation in the skin, synovium, entheses, tendons,
periosteum, bone, and gut [108]. Key effector cells and
cytokines change according to the tissue involved and
chronology of the disease. Th1 and Th/c17-mediated
inflammation is the hallmark of PsA with the key cytokines
TNF-α, IL-1β, -9, 23, -17, and -22 [108]. Although these
cells and cytokines have pathogenetic impacts in any
autoimmune disease, findings of clear autoreactivity
presumable to reflect immunity to self (neo)antigens and
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loss of tolerance will be reviewed here.
2.2.1. Potentially autoreactive T cells in PsA
The cellular infiltrate in the psoriatic skin, synovium,
and inflammatory enthesis is similar and predominantly
lymphocytic [109]. Although the T cells (mainly CD8+)
are predominant in the synovial fluid and entheseal
inflammation, B cells may occasionally form germinal
centers (i.e. ectopic lymphoid neogenesis) in the affected
synovia [109]. A subset of synovial fluid and synovial CD8+
T cells show TCR oligoclonality suggesting an antigen
driven response in PsA [109,110]. Although no autoantigen
could be identified for these (oligo)clonal CD8+ T cells
with highly homologous complementarity-determining
regions, they are present in the effector memory cell
phenotype in the systemic circulation as well [111]. Upon
stimulation, IL-17 and IFN-γ/IL-17 double producing T
cells were expanded in this peripheral CD8+ T cell subset
with ability to migrate to synovial fluid.[111] Interestingly,
CD4+Foxp3+ regulatory T (Treg) cells were shown to be
induced to secrete IL-17 and lose suppressor activity
(exTreg cells) in the inflamed tissue microenvironment in
PsA [112]. This may lead to loss of immune tolerance. The
role of antigen presenting cells such as dendritic cells and
macrophages in the context of autoimmunity remains to
be elucidated in the pathogenesis of PsA.
2.2.2. Autoantibodies in PsA
Although autoantibodies such as rheumatoid factor (RF),
anticitrullinated peptide (ACPA), antinuclear (ANA),
and antineutrophilic cytoplasmic (ANCA) antibodies
may occasionally be encountered in PsA patients’
sera, their role in disease pathogenesis is not clear but
ACPA, being present in only 0.9% to 17.5%, was found
to be associated with polyarticular and erosive disease
[113]. ANA prevalence was similar or slightly increased
compared to that of general population if patients on
biologics were excluded [113,114]. Other autoantibodies
implicated in RA such as antimutated citrullinated
vimentin (anti-MCV) and anticarbamylated peptide (antiCarP) were reported to be present in up to one third of
the PsA patients and proposed to be used as diagnostic/
prognostic disease markers [113,114]. Beyond these
shared autoantibodies, more specific ones with possible
roles in disease pathogenesis were identified. Anti-PsA
peptide antibody was detected in the sera of 85% of the
PsA and 8% of the RA patients while not present in healthy
controls’ sera [115]. It was present only in 3.3% patients
with psoriasis and not detected in the sera of patients with
SLE, Sjögren’s syndrome, SSc, and ankylosing spondylitis
[115]. This PsA peptide (TNRRGRGSPGAL dodecamer)
exhibited sequence homology with cutaneous (fibrillin-3,
desmocollin-3, and keratin-78) and entheseal antigens
(nebulin-related anchoring protein, N-RAP) and with IL17B and toll-like receptor 2 (TLR2) [115]. PsA patients’
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sera cross-reacted with these cutaneous and entheseal
autoantigens and TLR2 [115]. Two antigens expressed in
the psoriatic skin, ADAMTSL5 and a cathelicidin, LL-37,
towards which an autoimmune activity was shown to be
directed in psoriasis, were identified as autoantigens in
PsA as well [116]. IgG autoantibodies against ADAMTSL5
and LL-37 were shown to be present in PsA even with
higher concentrations than in psoriasis-only patient sera
significant enough to differentiate PsA and psoriasis [116].
Interestingly, SLE but not atopic dermatitis controls were
reported to have anti-ADAMTSL5 and anti-LL-37 IgG
serum levels similar to those of psoriasis patients [116].
Neutrophil extracellular trap (NET)-derived DNA-LL-37
complex was shown to be able to activate B cells leading
to anti-LL-37/anti-NET autoantibody production in
SLE [117]. Although implicated as a potential source of
autoantibodies in psoriasis, [118] NETosis was not studied
in PsA. More than 40 different antibodies (eight of which
were present in more than half of the patients with 2.86
to 10.59 times higher serum levels compared to healthy
people) to autoantigens have been identified in psoriasis to
date [116] and most remain to be studied in PsA.
3. Clinical observations
Given the shared genetic risk factors and
immunopathological mechanisms, PsA patients may
be expected to have more frequent autoimmune
multimorbidity. Although controlled studies are lacking,
autoimmune diseases such as SLE, celiac disease, vitiligo,
and thyroid autoimmunity seem to be more frequent in
PsA than that expected in the population (Table 2) [119–
125]. These observations should be confirmed in large
PsA cohorts. The opposite may also be true but difficult to
demonstrate particularly if the autoimmune disease itself
is arthritic. If one considers a research on the frequency of
RA in patients with psoriatic disease, the diagnoses will be
equivocal in many cases. Similarly, it is quite difficult to
conduct a research on the prevalence of psoriatic disease
in RA. Nevertheless, psoriasis was reported to be more
frequent than expected in large SLE and SSc cohorts and
in MS although no PsA data were provided [126–128].
Lastly, treatment response to co-stimulation inhibiton
and calcineurin/mammalian target of rapamycin (mTOR)
inhibiton may suggest contribution of autoimmunity to
inflammation in PsA. B-cell depletion with rituximab may
have some efficacy in PsA patients with long-standing
disease [129]. Pleitropic drugs such as corticosteroids
and conventional disease-modifying antirheumatic drugs
commonly used in the treatment of PsA are effective in
systemic autoimmune diseases as well. Clinical trials of
biological drugs targeting IL-23 and IL-17, which are the
cornerstones in treatment of psoriatic disease, are under
way with preliminary success in autoimmune diseases
such as SLE and MS [130,131].
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Table 2. The prevalence of selected autoimmune diseases in psoriatic arthritis.

Autoimmune Disease
Thyroid Autoimmunity*

Prevalence
Psoriatic Arthritis

Prevalence
Control Group

Ref.

33/97 (34%)

15/97 (15.5%)

121

F:12/36 (33.3%)

F:33/180 (18.3%)

122

M:11/44 (25%)

M:10/220 (4.5%)

122

Systemic Lupus Erythematosus

18/4836 (0.37%)

36/24180 (0.15%)

123

Sjögren’s Syndrome

1/41 (2.4%)

-

124

11/3161 (0.35%)

74/31610 (0.23%)

125

5/114 (4.4%)

-

126

Polymyositis & Dermatomyositis

2/1228 (0.16%)‡

-

127

Inclusion Body Myositis

2/1228 (0.16%)

-

Vitiligo

3/114 (2.6%)†

-

126

Alopecia Areata

1/114 (0.9%)

-

126

Atrophic Gastritis

1/114 (0.9%)

-

126

Celiac Disease

‡

†

Idiopathic Inflammatory Myopathies

Abbreviations: F = Female, M = Male.
*with or without thyroid dysfunction †higher than the expected prevalence in the population. ‡ Two
cases of systemic lupus erythematosus and one dermatomyositis were probably caused by TNF-α
inhibitor use.

4. Conclusion
The pathogenesis of the PsA is largely unknown. But there
is some evidence of autoimmunity in PsA as suggested
by genetic changes shared by a variety of autoimmune

and immune mediated inflammatory diseases,
immunopathological findings such as synovial oligoclonal
CD8+ T cells and circulating autoantibodies, and clinical
observations of autoimmune multimorbidity.
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